The Biotech Story Wall Street Could Be All Over in 2026. ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Small Caps Daily._
-------------------------
YD BIO LTD. (NASDAQ: YDES) IS PIONEERING THE NEXT ERA OF CANCER
DIAGNOSTICS AND ADVANCED EYE CARE WHILE DRIVING COMMERCIAL REVENUE
RIGHT NOW.
[YDES] [[link removed]]
YD BIO LTD. (NASDAQ: YDES) [[link removed]] is setting
itself apart by turning breakthrough science into commercial
solutions. THE COMPANY’S OKAIDX™ LIQUID BIOPSY PLATFORM NOW
ENABLES EARLY DETECTION OF PANCREATIC, COLORECTAL, AND BREAST CANCERS
ACROSS MOST OF THE U.S., COMBINING NON-INVASIVE TESTING WITH AT-HOME
BLOOD COLLECTION AND TELEHEALTH SUPPORT. At the same
time, YDES’S _FDA-cleared _Exovisse® contact lenses and
artificial tears are GENERATING NEAR-TERM REVENUE while laying the
foundation for next-generation regenerative therapies. With 20-year
strategic agreements with EG Biomed and 3D Global Biotech, YDES has
secured exclusive access to advanced molecular diagnostics and stem
cell-derived exosome therapies, positioning itself at the forefront of
two of healthcare’s fastest-growing markets.
YDES isn’t waiting for approvals or hypothetical breakthroughs —
it’s already in the market, scaling its diagnostics and eye care
solutions while building a robust pipeline for the future. From U.S.
expansion with a new California operations hub to growing clinical
validation of its early cancer detection platform, YDES is combining
execution, innovation, and strategic partnerships for long-term
impact.
In 2026, YDES could redefine what it means to be a biotech leader.
By turning liquid biopsy technology into a nationwide cancer detection
platform and pairing it with regenerative ocular therapies, YD Bio is
tackling two of healthcare’s fastest-growing markets simultaneously.
EXPLORE HOW YDES IS POSITIONED AT THE CENTER OF TWO OF HEALTHCARE’S
FASTEST-GROWING MARKETS. [[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of YD Bio Ltd. (NASDAQ: YDES). The compensation consists of up to
$6,500 and was received/will be received from Interactive Offers.
This communication should not be considered as an endorsement of the
securities of adviser YD Bio Ltd. (NASDAQ: YDES) and we are not
responsible for any errors or omissions in any information provided
about the securities of YD Bio Ltd. (NASDAQ: YDES) or Interactive
Offers.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 1/7/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
